Safety of mesenchymal stromal cell therapy for inflammatory bowel diseases: Results of a 5-year follow-up

Safety of mesenchymal stromal cell therapy for inflammatory bowel diseases: Results of a 5-year follow-up

Aim. To compare the safety of therapy in patients with ulcerative colitis (UC) and Crohn's disease (CD) who have received combination anti-inflammatory therapy using bone marrow mesenchymal stromal cells (MSC) and standard therapy with 5-aminosalicylic acid, glucocorticosteroids, and immunosupp...

Full description

Bibliographic Details
Main Authors: O V Kniazev, A I Parfenov, A G Konopliannikov, I N Ruchkina, A A Churikova, S V Bykova, E A Albulova, O N Boldyreva, N A Fadeeva, A A Lishchinskaia
Format: Article
Language:Russian
Published: "Consilium Medicum" Publishing house 2015-02-01
Series:Терапевтический архив
Subjects:
safety of cell therapy
mesenchymal stromal cells
crohn's disease
ulcerative colitis
inflammatory bowel diseases
Online Access:https://ter-arkhiv.ru/0040-3660/article/view/31691

Internet

https://ter-arkhiv.ru/0040-3660/article/view/31691

Similar Items